Proteomics technology company Oxford Genome Sciences (OGeS) is collaborating with Bayer HealthCare AG Diagnostics Division to apply its proteomics platform, in conjunction with its Oxford Genome Anatomy Project (OGAP), to evaluate novel candidate biomarkers that may have important applications in clinical care for the diagnosis and prognostic assessment of breast cancer. Under the agreement, Bayer Diagnostics will provide program funding and performance-related payments to OGeS.
BIACORE BUYS HTS
Biacore International has acquired HTS Biosystems for $4 million in cash. The acquisition, which includes HTS' FLEXChip System and related assets, will extend Biacore's product offering. The FLEXChip System provides an open, array-based platform for kinetic screening, and uses surface plasmon resonance for real-time interaction analysis.
Sirna Therapeutics is the first publicly traded biotech company to choose San Francisco's new China Basin Landing at Mission Bay as its headquarters. Sirna, an RNA interference biotech formerly based in Boulder, Colo., since its founding in April 2003, will be adjacent to University of California at San Francisco's 43-acre life science campus at Mission Bay.